Agios Pharmaceuticals, Inc. (AGIO)
NASDAQ: AGIO · Real-Time Price · USD
28.14
-0.65 (-2.26%)
At close: May 22, 2026, 4:00 PM EDT
27.84
-0.30 (-1.05%)
After-hours: May 22, 2026, 7:42 PM EDT
Agios Pharmaceuticals Employees
As of December 31, 2025, Agios Pharmaceuticals had 540 total employees, including 539 full-time and 1 part-time employees. The number of employees increased by 52 or 10.66% compared to the previous year.
Employees
540
Change (1Y)
52
Growth (1Y)
10.66%
Revenue / Employee
$122,311
Profits / Employee
-$782,598
Market Cap
1.67B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 540 | 52 | 10.66% | 539 | 1 |
| Dec 31, 2024 | 488 | 102 | 26.42% | 486 | 2 |
| Dec 31, 2023 | 386 | -7 | -1.78% | 383 | 3 |
| Dec 31, 2022 | 393 | 1 | 0.26% | 389 | 4 |
| Dec 31, 2021 | 392 | -170 | -30.25% | 390 | 2 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Recursion Pharmaceuticals | 600 |
| AbCellera Biologics | 562 |
| Intellia Therapeutics | 377 |
| Nuvation Bio | 307 |
| Harmony Biosciences Holdings | 293 |
| Capricor Therapeutics | 231 |
| Monte Rosa Therapeutics | 187 |
| Innoviva | 159 |
AGIO News
- 3 days ago - Agios announces EC grants marketing authorization for PYRUKYND - TheFly
- 3 days ago - Avanzanite Bioscience's Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia - Business Wire
- 3 days ago - Agios' PYRUKYND® (mitapivat) Approved in the European Union for Adults with Thalassemia - GlobeNewsWire
- 6 days ago - Agios Pharmaceuticals Touts Strong AQVESME Launch as Sickle Cell Filing Advances - MarketBeat
- 6 days ago - Agios Pharmaceuticals Transcript: RBC Capital Markets Global Healthcare Conference 2026 - Transcripts
- 13 days ago - Agios Pharma submits sNDA to FDA for U.S. accelerated approval of mitapivat - TheFly
- 13 days ago - Agios Pharmaceuticals to present mitapivat data at EHA Congress - TheFly
- 13 days ago - Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease - GlobeNewsWire